Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Total Liabilities (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Total Liabilities for 6 consecutive years, with $77.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 49.2% to $77.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $77.4 million, a 49.2% decrease, with the full-year FY2025 number at $77.4 million, down 49.2% from a year prior.
  • Total Liabilities was $77.4 million for Q4 2025 at Lexicon Pharmaceuticals, down from $85.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $174.6 million in Q1 2025 to a low of $74.7 million in Q1 2023.
  • A 3-year average of $122.4 million and a median of $131.9 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: soared 71.89% in 2024, then plummeted 49.2% in 2025.
  • Lexicon Pharmaceuticals' Total Liabilities stood at $136.3 million in 2023, then rose by 11.85% to $152.5 million in 2024, then tumbled by 49.2% to $77.4 million in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Total Liabilities are $77.4 million (Q4 2025), $85.8 million (Q3 2025), and $96.1 million (Q2 2025).